SCHEMBL5069145

SCHEMBL5069145

CCOC(=O)c1cnc2cc(CO)nn2c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.49
CYP2C19 P33261 3/20 0.42
CYP2C9 P11712 1/20 0.42
CYP1A2 P05177 2/20 0.41
CYP2D6 P10635 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
CA12 O43570 2/20 0.41
CA1 P00915 2/20 0.41
CA2 P00918 2/20 0.41
CA7 P43166 2/20 0.41
CA9 Q16790 2/20 0.41
CA14 Q9ULX7 2/20 0.41
KDM4E B2RXH2 4/20 0.40
GLA P06280 3/20 0.40
GAA P10253 3/20 0.40
JMJD6 Q6NYC1 3/20 0.40
MAP4K4 O95819 1/20 0.40
ALDH1A1 P00352 2/20 0.40
HPGD P15428 2/20 0.40
NPC1 O15118 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5068335 0.88 LMNA (0.46) LMNACYP2C19CYP2C9CYP1A2CYP2D6
SCHEMBL28448526 0.87 LMNA (0.65) LMNACYP2C19CYP2C9CYP1A2CYP2D6
SCHEMBL31329101 0.85 LMNA (0.48) LMNACYP2C19CYP2C9CYP1A2CYP2D6
SCHEMBL31351998 0.85 LMNA (0.51) LMNACYP2C19CYP2C9CYP1A2CYP2D6
SCHEMBL23540360 0.84 HDAC6 (0.46) LMNACYP2C19CYP2C9CYP1A2KDM4E
SCHEMBL5070925 0.79 KDM4E (0.49) LMNAKDM4EGAAALDH1A1HPGD
SCHEMBL30512047 0.79 KIT (0.50) CYP2C19CYP2C9CYP1A2KDM4EGAA
SCHEMBL21639018 0.78 LMNA (0.47) LMNACYP2C19CYP1A2NPSR1KDM4E
SCHEMBL3611630 0.76 MAP4K4 (0.46) LMNACYP1A2CA12CA1CA2
SCHEMBL12340906 0.76 ALDH1A1 (0.42) LMNACYP2C19CYP2C9CYP1A2CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1595866-B1 Cyanopyrrolidines useful for the treatment of inter alia metabolic syndrome SANWA KAGAKU KENKYUSHO CO (JP) 2016-06-08 EP disclosed
US-7345180-B2 Compound inhibiting dipeptidyl peptidase IV SANWA KAGAKU KENKYUSHO CO., LTD. (JP) 2008-03-18 US disclosed
US-20060229286-A1 Compound inhibiting dipeptidyl peptidase IV SANWA KAGAKU KENKYUSHO CO., LTD. (JP) 2006-10-12 US disclosed
EP-1595866-A1 COMPOUND INHIBITING DIPEPTIDYL PEPTIDASE IV Sanwa Kagaku Kenkyusho Co., Ltd. (JP) 2005-11-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060229286-A1 Compound inhibiting dipeptidyl peptidase IV DPP4, DPP3, DPP7 LMNA 4436/4885CYP2C19 613/4885CYP2C9 391/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.